WaveMan
WaveMan · Company
FLGT · Fulgent Genetics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

FLGT Fulgent Genetics (FLGT) Insider Trading, Ownership & Congress Trades

Healthcare Services · Services-medical laboratories · CIK 0001674930
Quote by TradingView
Form 144 · 4
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
62
13F, latest reported quarter

What the filings say about FLGT

Insiders, 180 days
-$223.5K net sold
2 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$117.1K
4 notices

Fulgent Genetics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Fulgent Genetics, Inc. insiders sold a net $223.5K of stock across 106 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Gao Hanlin
Chief Scientific Officer
SELL
2026-09-03 SECtraded 2026-09-02
1,673
$32.9K
+2.5%
Context
  • 26 earlier Form 4 trades (code P or S) here by this insider (26 sales), the last on Aug 27, 2026.
  • The trade is 0.2% of the 986,117 shares held after it.
  • 1 other insider sold within 30 days.
  • 62 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Gao Hanlin sold about $32.9K of FLGT on Sep 2, 2026; 1 other insider sold within 30 days and 62 funds added in the latest 13F quarter.
Xie Jian
President and COO
SELL
2026-09-03 SECtraded 2026-09-02
2,127
$41.8K
+2.5%
Context
  • 39 earlier Form 4 trades (code P or S) here by this insider (39 sales), the last on Aug 27, 2026.
  • The trade is 0.6% of the 359,924 shares held after it.
  • 1 other insider sold within 30 days.
  • 62 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and COO Xie Jian sold about $41.8K of FLGT on Sep 2, 2026; 1 other insider sold within 30 days and 62 funds added in the latest 13F quarter.
Xie Jian
President and COO
SELL
2026-08-28 SECtraded 2026-08-27
1,193
$23.7K
+4.4%
Context
  • 38 earlier Form 4 trades (code P or S) here by this insider (38 sales), the last on Jun 2, 2026.
  • The trade is 0.3% of the 362,051 shares held after it.
  • 1 other insider sold within 30 days.
  • 62 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and COO Xie Jian sold about $23.7K of FLGT on Aug 27, 2026; 1 other insider sold within 30 days and 62 funds added in the latest 13F quarter.
Gao Hanlin
Chief Scientific Officer
SELL
2026-08-28 SECtraded 2026-08-27
939
$18.7K
+4.4%
Context
  • 25 earlier Form 4 trades (code P or S) here by this insider (25 sales), the last on Jun 2, 2026.
  • The trade is 0.1% of the 987,790 shares held after it.
  • 1 other insider sold within 30 days.
  • 62 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Gao Hanlin sold about $18.7K of FLGT on Aug 27, 2026; 1 other insider sold within 30 days and 62 funds added in the latest 13F quarter.
Xie Jian
President and COO
SELL
2026-06-03 SECtraded 2026-06-02
2,146
$38.4K
+3.7%
Context
  • 37 earlier Form 4 trades (code P or S) here by this insider (37 sales), the last on May 27, 2026.
  • The trade is 0.6% of the 367,605 shares held after it.
  • 1 other insider sold within 30 days.
  • 62 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and COO Xie Jian sold about $38.4K of FLGT on Jun 2, 2026; 1 other insider sold within 30 days and 62 funds added in the latest 13F quarter.
106 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 101 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$223.5K over 180 days
-$117.1K over 90 days
more than 67% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
62 funds bought in last quarter
below 76% of Healthcare Services
Revenue
+13.8% year over year
more than 53% of Healthcare Services
Margin
-18.8% net margin
below 76% of Healthcare Services
Buybacks
$63.9M repurchased, FY to 2026-06-30
more than 55% of Healthcare Services
Short interest
12.8% of the float short (float per yahoo 2026-10-27) · 7.4 days to cover · settled 2026-10-15
more than 79% of Healthcare Services
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch FLGT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-14.4%12M
-42%-18%+7%+31%2025-102025-122026-022026-042026-062026-082026-10 2025-11-19 · Xie Jian sold $291.0K2026-09-02 · Xie Jian sold $41.8K2026-06-02 · Xie Jian sold $38.4K2025-11-28 · Xie Jian sold $35.4K2026-09-02 · Gao Hanlin sold $32.9K2025-12-02 · Xie Jian sold $32.3K2025-12-02 · Gao Hanlin sold $30.5K2026-06-02 · Gao Hanlin sold $30.2K2025-11-28 · Gao Hanlin sold $27.9K2026-08-27 · Xie Jian sold $23.7K2026-05-27 · Xie Jian sold $21.1K2025-11-24 · Xie Jian sold $20.8K2026-08-27 · Gao Hanlin sold $18.7K2026-05-27 · Gao Hanlin sold $16.6K2025-11-24 · Gao Hanlin sold $16.3K2026-09-02 · Gao Hanlin filed to sell $32.9K2026-09-02 · Xie Jian filed to sell $41.8K2026-08-27 · Gao Hanlin filed to sell $18.7K2026-08-27 · Xie Jian filed to sell $23.7K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns FLGT: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
2,286,669 sh
$46.9M
VANGUARD CAPITAL MANAGEMENT LLC
789,498 sh
$16.2M
JACOBS LEVY EQUITY MANAGEMENT, INC
782,116 sh
$16.0M
JPMORGAN CHASE & CO
756,558 sh
$15.5M
Diametric Capital, LP
697,784 sh
$14.3M

Congress trades in FLGT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

FLGT planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Gao Hanlin
Filed 2026-09-02
$32.9K
Xie Jian
Filed 2026-09-02
$41.8K
Gao Hanlin
Filed 2026-08-27
$18.7K
Xie Jian
Filed 2026-08-27
$23.7K

FLGT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
State Street(R) SPDR(R) S&P(R) Health Care Services ETF
$1.1M position · as of 2026-06-30
0.8%
NVIT Small Cap Value Fund
$1.3M position · as of 2026-06-30
0.6%
Invenomic Fund
$4.4M position · as of 2026-07-31
0.5%
ALPS Medical Breakthroughs ETF
$583.9K position · as of 2026-05-31
0.4%
Global X Genomics & Biotechnology ETF
$200.1K position · as of 2026-05-31
0.4%
Columbia Variable Portfolio - Small Cap Value Discovery Fund
$1.5M position · as of 2026-06-30
0.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$6.2M
$9.5M
$2.6M
-50%
+20%
2024
$6.1M
$4.1M
$2.2M
-65%
-9%
2023
$5.3M
$5.0M
$1.7M
-45%
-8%
2022
$5.2M
$3.4M
$3.8M
-43%
-11%
2021
$5.7M
$5.7M
$758.2K
+93%
-1%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $223.5K sold by insiders over 180 days, 62 funds added last quarter, $117.1K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
NTRACSTLPGNYHIMSWGSPRVATDOCAVAHGHADUSSERABDSX

FLGT financials

Revenue growth
+13.8%
XBRL, annual
Net margin
-18.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$323.9M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-26.0%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$103.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-8.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-7.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-11.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-18.7%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$322.7M$283.5M$289.2M$619.0M
Gross profit$130.9M$107.2M$104.5M$366.9M
Operating income-$91.1M-$73.9M-$195.5M$178.5M
Net income-$60.5M-$42.7M-$167.8M$143.4M
Operating cash flow-$101.6M$21.1M$27.0M$253.5M
Cash$50.2M$55.1M$97.5M$79.5M
Buybacks$10.9M$225.0K$25.1M$74.3M
SEC XBRL, fiscal years, as known on 2026-10-28

FLGT Stock Sonar score 5/7 axes

Find similar shapesCompare

FLGT ranks highest on growth (53rd percentile) and profitability (37th), and lowest on risk and compliance (23rd), among Healthcare Services peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
37
Inputs
  • Return on equity-8.0% · 42 pct, sector of 70
  • Return on assets-7.4% · 39 pct, sector of 88
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-11.4% · 30 pct, sector of 68
Growth
53
Inputs
  • Revenue growth, YoY+13.8% · 53 pct, sector of 87
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
33
Inputs
  • Net Form 4 buying (codes P and S), 180d-$223K · 65 pct, sector of 64
  • Insider buyers, 180d0 · 0 pct, sector of 64
Institutional and government
24
Inputs
  • Funds adding, latest quarter62 · 24 pct, sector of 73
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
23
Inputs
  • Short interest, % of float+12.8% · 18 pct, sector of 93
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+14.4% · 27 pct, sector of 72
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

FLGT filings, in plain words

Are Fulgent Genetics insiders buying or selling FLGT?

In the 180 days to 2026-10-28, Fulgent Genetics insiders were net sellers, a net $223.5K across purchases and sales reported on Form 4, by 2 sellers.

Are there planned insider sales of FLGT?

Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $117.1K of stock; the latest, by Gao Hanlin, was filed 2026-09-02.

Read the full summary

In the 180 days to 2026-10-28, Fulgent Genetics insiders were net sellers of FLGT, a net $223.5K across purchases and sales reported on Form 4 by 2 sellers. None of the 8 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $117.1K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies